Download PDF
CC BY-NC-ND 4.0 · J Lab Physicians 2019; 11(01): 034-038
DOI: 10.4103/JLP.JLP_72_18
Original Article

A 5-year surveillance on antimicrobial resistance of Acinetobacter isolates at a level-I trauma centre of India

Minu Kumari
Division of Trauma Surgery and Critical Care, JPNATC, AIIMS, New Delhi, India
,
Priyam Batra
Department of Microbiology, JPNATC, AIIMS, New Delhi, India
,
Rajesh Malhotra
Department of Orthopaedics, AIIMS, New Delhi, India
,
Purva Mathur
Department of Laboratory Medicine, JPNATC, AIIMS, New Delhi, India
› Author Affiliations Financial support and sponsorship: Nil
› Further Information
Also available at
  PDF Download Permissions and Reprints

Abstract

INTRODUCTION: Acinetobacter spp. has emerged as a major cause of nosocomial outbreaks. Multiple antibiotic resistance is an important problem in Acinetobacter isolates in recent years. The aim of this study was to evaluate the rate of antimicrobial resistance and changes in resistance pattern over a period of 5 years (2012–2016) in Acinetobacter spp. isolated from trauma patients.

MATERIALS AND METHODS: Acinetobacter spp. was identified by VITEK 2 and antibiotic susceptibility of isolates was investigated by disc-diffusion method and VITEK 2 automated system. Interpretation of susceptibility results was based on the Clinical and Laboratory Standards Institute guidelines.

RESULTS: Out of the total 16,210 isolates obtained throughout the period of 5 years, Acinetobacter spp. accounted for 3744 (28.9%). Out of which, the species which was maximally isolated was Acinetobacter baumannii (98.5%), followed by Acinetobacter lwoffii (1.4%) and Acinetobacter hemolyticus (0.1%). The highest number of clinical isolates of Acinetobacter were recovered from neurosurgical ward (n = 1210), followed by the neurosurgical intensive care unit (ICU) (n = 1000) and surgical ICU (n = 948) and the most common sample of Acinetobacter isolation was from tracheal aspirate (37.1%), followed by wound swab (18.8%). The highest level of resistance was observed against ciprofloxacin (96%), followed by cefepime (95%), ceftazidime (95%), piperacillin (95%), and amikacin (92%). The trend of antibiotic resistance was found to be statistically significant (P < 0.001) for most of the antibiotics being tested such as amikacin and carbapenems.

CONCLUSION: The high rate of antibiotic resistance of the Acinetobacter strains indicated that there is an urgent need for controlled antibiotic usage and appliance of hospital infection control measures.

Key words

Antimicrobial - infection - resistance - surveillance


Publication History

Received: 26 May 2018

Accepted: 15 October 2018

Article published online:
06 April 2020

© 2019.

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States; 2013. Available from: http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf. [Last accessed on 2018 May 02].
  • 2 Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012;18:268-81.
  • 3 Nelson RE, Schweizer ML, Perencevich EN, Nelson SD, Khader K, Chiang HY, et al. Costs and mortality associated with multidrug-resistant healthcare-associated Acinetobacter infections. Infect Control Hosp Epidemiol 2016;37:1212-8.
  • 4 Antunes LC, Visca P, Towner KJ. Acinetobacter baumannii: Evolution of a global pathogen. Pathog Dis 2014;71:292-301.
  • 5 Maragakis LL, Perl TM. Acinetobacter baumannii: Epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis 2008;46:1254-63.
  • 6 Liu WL, Liang HW, Lee MF, Lin HL, Lin YH, Chen CC, et al. The impact of inadequate terminal disinfection on an outbreak of imipenem-resistant Acinetobacter baumannii in an Intensive Care Unit. PLoS One 2014;9:e107975.
  • 7 Souli M, Galani I, Giamarellou H. Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe. Euro Surveill 2008;13. pii: 19045.
  • 8 Kwon KT, Oh WS, Song JH, Chang HH, Jung SI, Kim SW, et al. Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia. J Antimicrob Chemother 2007;59:525-30.
  • 9 Clinical and Laboratory Standard Institutes (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. CLSI Supplement M100. 27th ed. Wayne PA: Clinical and Laboratory Standard Institutes; 2017.
  • 10 Falagas ME, Mourtzoukou EG, Polemis M, Vatopoulos AC; Greek System for Surveillance of Antimicrobial Resistance. Trends in antimicrobial resistance of Acinetobacter baumannii clinical isolates from hospitalised patients in Greece and treatment implications. Clin Microbiol Infect 2007;13:816-9.
  • 11 García-Garmendia JL, Ortiz-Leyba C, Garnacho-Montero J, Jiménez-Jiménez FJ, Pérez-Paredes C, Barrero-Almodóvar AE, et al. Risk factors for Acinetobacter baumannii nosocomial bacteremia in critically ill patients: A cohort study. Clin Infect Dis 2001;33:939-46.
  • 12 Punpanich W, Nithitamsakun N, Treeratweeraphong V, Suntarattiwong P. Risk factors for carbapenem non-susceptibility and mortality in Acinetobacter baumannii bacteremia in children. Int J Infect Dis 2012;16:e811-5.
  • 13 Jaggi N, Sissodia P, Sharma L. Acinetobacter baumannii isolates in a tertiary care hospital: Antimicrobial resistance and clinical significance. J Microbiol Infect Dis 2012;2:57-63.
  • 14 Nazmul MH, Jamal H, Fazlul MK. Acinetobacter species-associated infections and their antibiotic susceptibility profiles in Malaysia. Biomed Res India 2012;23:571-5.
  • 15 Chuang YC, Sheng WH, Li SY, Lin YC, Wang JT, Chen YC, et al. Influence of genospecies of Acinetobacter baumannii complex on clinical outcomes of patients with Acinetobacter bacteremia. Clin Infect Dis 2011;52:352-60.
  • 16 Obeidat N, Jawdat F, Al-Bakri AG, Shehabi AA. Major biologic characteristics of Acinetobacter baumannii isolates from hospital environmental and patients’ respiratory tract sources. Am J Infect Control 2014;42:401-4.
  • 17 Xu J, Sun Z, Li Y, Zhou Q. Surveillance and correlation of antibiotic consumption and resistance of Acinetobacter baumannii complex in a tertiary care hospital in Northeast China, 2003-2011. Int J Environ Res Public Health 2013;10:1462-73.
  • 18 Özgür ES, Horasan ES, Karaca K, Ersöz G, Naycı Atış S, Kaya A. Ventilator-associated pneumonia due to extensive drug-resistant Acinetobacter baumannii: Risk factors, clinical features, and outcomes. Am J Infect Control 2014;42:206-8.
  • 19 Queenan AM, Pillar CM, Deane J, Sahm DF, Lynch AS, Flamm RK, et al. Multidrug resistance among Acinetobacter spp. in the USA and activity profile of key agents: Results from CAPITAL surveillance 2010. Diagn Microbiol Infect Dis 2012;73:267-70.